Systemic Moxifloxacin in Streptococcus viridans Endophthalmitis

Area of Science:

• Ophthalmology
• Infectious Diseases
• Pharmacology

Background:

• Endophthalmitis, an inflammation of the eye's interior, poses a significant risk following intraocular procedures.
• Streptococcus viridans is a common causative agent of bacterial endophthalmitis.
• Prophylactic antibiotic strategies are crucial for preventing post-operative infections.

Purpose of the Study:

• To assess the efficacy of systemic moxifloxacin as a prophylactic treatment against Streptococcus viridans endophthalmitis.
• To evaluate the impact of moxifloxacin on clinical and histopathological outcomes in a rabbit model.

Main Methods:

• Sixty rabbits were allocated into three groups: moxifloxacin, vancomycin, and saline control.
• Animals received intravenous antibiotics or saline, followed by intravitreal injection of S. viridans.
• Clinical assessments, bacterial cultures, and histopathological examinations were performed over seven days.

Main Results:

• The moxifloxacin group exhibited significantly lower clinical scores and bacterial loads compared to controls.
• Histopathological analysis revealed reduced inflammation and better retinal preservation in eyes treated with moxifloxacin.
• Systemic moxifloxacin demonstrated a protective effect against S. viridans-induced endophthalmitis.

Conclusions:

• Systemic moxifloxacin shows promise as a prophylactic agent for preventing Streptococcus viridans endophthalmitis.
• This finding supports the potential use of moxifloxacin in mitigating infection risk after intraocular surgeries.
• Further clinical studies are warranted to confirm these prophylactic benefits in human patients.